JOURNAL OF MICROSCOPY-OXFORD, 166, RP5–RP6. X-RAY STEREOMICROSCOPY - HIGH-RESOLUTION 3-D IMAGING OF HUMAN SPERMATOZOA IN AQUEOUS SUSPENSION WITH NATURAL CONTRAST. W., Williams, S., Meizel, S., & Rothman, S. X-RAY STEREOMICROSCOPY - HIGH-RESOLUTION 3-D IMAGING OF HUMAN SPERMATOZOA IN AQUEOUS SUSPENSION WITH NATURAL CONTRAST.TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 4(3), 227–234. Optical detection of tumors in vivo by visible light tissue oximetry. Optical detection of tumors in vivo by visible light tissue oximetry.Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report. Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report.JOURNAL OF MICROSCOPY-OXFORD, 204, 69–86. A new sample preparation method for biological soft X-ray microscopy: nitrogen-based contrast and radiation tolerance properties of glycol methacrylate-embedded and sectioned tissue. A new sample preparation method for biological soft X-ray microscopy: nitrogen-based contrast and radiation tolerance properties of glycol methacrylate-embedded and sectioned tissue.Automatic image acquisition, calibration and montage assembly for biological X-ray microscopy. Automatic image acquisition, calibration and montage assembly for biological X-ray microscopy.He is certified by the American Board of Radiology in Radiation Oncology, and is a Fellow of the American Society for Radiation Oncology (ASTRO) and a Fellow of the American College of Radiology (ACR). He completed his Radiation Oncology residency training at Stanford University. Loo received his MD from University of California, Davis and his PhD in Bioengineering from University of California, San Francisco and Berkeley. ![]() ![]() This program comprises both technology development and fundamental research on the radiobiology of extremely rapid FLASH therapy to optimize the biological therapeutic index.ĭr. ![]() Loo's major laboratory research focus has been to co-lead a collaborative effort between the Stanford Cancer Institute and SLAC National Accelerator Laboratory to develop PHASER into a transformative yet clinically practical technology. Since conceiving of a fundamentally new approach to delivering ultra-rapid, ultra-precise radiation therapy, pluridirectional high-energy agile scanning electronic radiotherapy (PHASER), Dr. He also co-leads clinical trials of novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias. As part of this work, he leads a clinical and preclinical research program in molecular imaging, particularly using novel PET tracers for tumor hypoxia (EF5), tumor proliferation (FLT), and neuroinflammation (PBR06). His clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. ![]() Loo is a recognized expert in thoracic cancers serving on multiple national committees (including as writing member or vice-chair) that publish clinical guidelines on the treatment of lung cancer and other thoracic malignancies, particularly the National Comprehensive Cancer Network (NCCN). His clinical specialties are state-of-the-art radiation therapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR) and 4-D image-guided radiation therapy for lung tumors. He is a physician-scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program at Stanford. Loo Jr., MD PhD is a Professor of Radiation Oncology, a member of the Stanford Cancer Institute, a member of the Molecular Imaging Program at Stanford (MIPS) in the Department of Radiology, and a member of Bio-X in the School of Medicine.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |